Company profile
Nanoptima - Developing revolutionary new controlled-release drug depots in Alderley Park, Cheshire.
NanOptima is developing revolutionary new controlled-release drug depots. NanOptima aims to radically improve the current standard of care for retinal diseases.
Financial period: 1 Mar 2024 to 28 Feb 2025
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
AA | Transaction MzQ0NDEwMzAwMmFkaXF6a2N4
Published 19 Nov 2024 11:47
SH01 | Transaction MzQzODkzNzczMWFkaXF6a2N4
Published 09 Oct 2024 02:46
AD01 | Transaction MzQzNDMwNTIxNGFkaXF6a2N4
Published 03 Sep 2024 12:29
AD01 | Transaction MzQzNDMwNDY3M2FkaXF6a2N4
Published 03 Sep 2024 12:24
Company registered at Companies House
1 Apr 2025 to 31 Mar 2026
NanOptima aims to address the significant burden of retinal diseases such as wet age-related macular degeneration(AMD), diabetic retinopathy, and retinal vein occlusion. These conditions affect approximately 570,000 people in the UK and over 96 million worldwide. Current treatments, which involve frequent intravitreal injections of anti-VEGF drugs every 1...
1 Jul 2022 to 31 Dec 2023
**NanOptima has a mission to reduce the colossal burden of treatment for retinal diseases, specifically "wet" age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion**. These conditions are estimated to affect 570,000 people in the UK and and at least 96M worldwide. Current proven protein drug treatments preserve sight, but requ...
1 May 2018 to 30 Apr 2019
"NanOptima has a mission to improve efficacy and safety of ophthalmic medications by improving delivery of APIs. As populations grow older, more and more people need treatment for sight-threatening eye conditions. ""The lifetime risk, of sight loss or blindness requiring intervention or treatment, is estimated to be: nearly **1 in 5 people for permanent s...
